Pfizer (PFE) topped Wall Street’s EPS and revenue estimates in the third quarter. Moreover, the company updated its guidance for fiscal 2022. Analysts expect the stock to rise more than…
Pfizer (PFE) topped Wall Street’s EPS and revenue estimates in the third quarter. Moreover, the company updated its guidance for fiscal 2022. Analysts expect the stock to rise more than…